Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

XBiotech is a biopharmaceutical company developing first-in-class antibody therapies. The Company’s lead product candidate inhibits chronic (sterile) inflammation – a condition involved in the progression of many serious and common diseases. The Company has several groundbreaking clinical trial programs in different areas of medicine including dermatology, oncology, diabetes, cachexia and cardiovascular disease.

Henan Commercial Science Research Institute Co., Ltd., established on 2004-12-06, Business scope includes food production technology,Quality Safety Control Technology,Scientific research in the fields of food anti-counterfeiting technology and research and development of related technical products;Research and development of bioengineering technology and products;Marketing planning and consulting services for food products;Realtor(certificate).

STROX Biopharmaceuticals LLC is an American private company located in Wellington, FL, that manufactures antibacterial products.

Ruizheng Haobo (Tianjin) Medical Equipment Sales Co., Ltd., established on 2013-03-28, Business scope includes Class III:6815injection puncture device,6821Medical electronic equipment,6823Medical Ultrasonic Instruments and Related Equipment,6825Medical high-frequency equipment,6828Medical MRI equipment,6846Implantable materials and artificial organs,6864Medical hygiene materials and dressings,6865Medical Suture Materials and Adhesives,6877Intervention equipment,Class II:6801Basic Surgical Instruments,6803Neurosurgical Instruments,6807Thoracic Cardiovascular Surgery Instruments,6810Orthopedic surgery(orthopedics)Surgical Instrument Wholesale.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Academisch Ziekenhuis Maastricht operates as medical research centre. The company is headquartered in Maastricht, the Netherlands.

Humabs currently has two clinical-stage partnered programs, validating the CellClone technologies and generating a significant revenue stream Humabs has a broad partnership with MedImmune, the global biologics research and development arm of AstraZeneca, that covers multiple pathogens. The most advanced of the projects is an antibody directed against influenza A virus. This antibody, called MEDI8852, has demonstrated activity against all known subtypes of the influenza A virus and is therefore less affected by the emergence of new strains. The program was partnered with MedImmune while still in preclinical development and has currently concluded the clinical phase 1b/2a. Data on this program have been published in the journals Science and Cell. Humabs has also partnered with Novartis for an antibody directed against an undisclosed target. This program is currently in phase 2.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Tianjin Ringpu Bio Technology they develop and produce bio- pharmaceutical products for veterinary medicines and vaccines. They are manufacturer and service provider of animal health products.